Abstract 11238: Blood Pressure-Lowering Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension: A Systematic Review, Meta-Analysis, and Dose-Response Analysis with Trial Sequential Analysis
Background: Resistant and uncontrolled hypertension carries high cardiovascular and renal risk, with aldosterone excess as a central driver. Baxdrostat, a highly selective aldosterone synthase (CYP11B2) inhibitor, was recently approved, yet prior syntheses pooled only a subset of trials or combined agents. We provid...